DWA
CBMG

Dorsey Wright & Associates’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Dorsey Wright & Associates’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-700
Closed -$13K – 366
2018
Q3 		$13K Buy
+700
New +$14.4K ﹤0.01% 254

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dorsey Wright & Associates's CBMG Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2018, closing a stake of 700 shares — an estimated $13K sold.

Dorsey Wright & Associates first reported a position in CBMG in Q3 2018 and held it in 1 quarter. The position peaked at $13K in Q3 2018. 35 funds tracked by Wall St. Rank hold CBMG as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 700 Cellular Biomedicine Group, Inc. shares in Q4 2018, an estimated $13K.
  • Dorsey Wright & Associates first reported a position in Cellular Biomedicine Group, Inc. in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Cellular Biomedicine Group, Inc. position peaked at $13K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.